Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab and Bortezomib in Relapsed CD20+ Lymphomas
NCT01397591Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Oct 2011
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab, bortezomib in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), sponsored by OHSU Knight Cancer Institute. Started Oct 2011; status: terminated.
02
Drugs
ofatumumabbortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01397591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01397591.